---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-022193"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2024-05-31T23:59:59+00:00"
generated_at: "2026-06-01T07:10:52.739223+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Oncocyte approves salary increases for CEO, interim CFO, and CSO effective May 20, 2024

## Summary
- CEO Joshua Riggs' base salary increased from $360,000 to $400,000.
- Interim CFO/Principal Accounting Officer James Liu's salary raised from $200,000 to $207,000.
- Chief Science Officer Ekkehard Schütz's salary rose from $351,525 to $378,025.

## SEC filing metadata
- accession: 0001493152-24-022193
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2024-05-31T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315224022193/0001493152-24-022193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315224022193/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-022193
- JSON: https://secwatch.observer/filing/0001493152-24-022193.json
- Plain text: https://secwatch.observer/filing/0001493152-24-022193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.